Neuland Laboratories Limited Earnings Summary — Q1 FY2027
Neuland Laboratories Reports Robust Q1 Growth with Revenue Up 119% and Strategic Gland Pharma Collaboration
Quarterly Business Intelligence
AI Quarterly Scorecard™
Computed deterministically from the last 10 reported quarters.
Quarterly Business Momentum
- Revenue declined 17.3% sequentially in Q1 FY2027.
- Revenue of ₹642 Cr is 119.2% higher year-on-year.
- Revenue has compounded at 25.5% annualised over the last 10 quarters.
- Net profit of ₹148 Cr is 962.4% above the same quarter last year.
- Profit growth is outpacing revenue growth, pointing to positive operating leverage.
- Net profit has compounded at 41.6% annualised across the period.
- Operating margin stands at 34.7% in Q1 FY2027.
- Operating margin expanded by 2296 bps year-on-year.
- Over the last two years operating margin has expanded by 668 bps.
- PBT margin is 30.8%.
- Expense growth of 62.1% remained below revenue growth of 119.2%.
- Operating profit of ₹223 Cr is 546.4% higher year-on-year.
- Operating leverage continues to improve.
- 4 of the last 6 measured quarters delivered year-on-year revenue growth.
- Overall quarterly business momentum scores 69/100 (Healthy) on the latest 10 quarters.
- Business momentum remains positive heading into the next quarter.
Quarterly Financials
Last 10 Reported Quarters • All figures in ₹ Crore • Margins in %
| Metric | Trend | Latest Q1 FY2027 | Q4 FY2026 | Q3 FY2026 | Q2 FY2026 | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 | Q4 FY2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | Improving | 642 | 776 | 440 | 514 | 293 | 328 | 398 | 311 | 440 | 385 |
| Expenses | Improving | 419 | 469 | 363 | 359 | 258 | 277 | 311 | 249 | 316 | 278 |
| Operating Profit | Volatile | 223 | 307 | 77 | 156 | 34 | 51 | 87 | 62 | 123 | 107 |
| Operating Margin | Volatile | 34.7% | 39.6% | 17.5% | 30.3% | 11.8% | 15.6% | 21.8% | 20.0% | 28.1% | 27.8% |
| Other Income | Volatile | 8 | 12 | 8 | 2 | 8 | 7 | 60 | 4 | 25 | 5 |
| Interest | Volatile | 7 | 7 | 7 | 5 | 5 | 2 | 2 | 1 | 3 | 4 |
| Depreciation | Improving | 27 | 25 | 24 | 23 | 20 | 17 | 16 | 16 | 16 | 16 |
| Profit Before Tax | Volatile | 198 | 287 | 54 | 129 | 18 | 39 | 128 | 49 | 130 | 92 |
| Tax | Volatile | 50 | 75 | 14 | 33 | 4 | 11 | 26 | 17 | 32 | 25 |
| Net Profit | Volatile | 148 | 213 | 41 | 97 | 14 | 28 | 102 | 33 | 98 | 68 |
| Net Margin | Volatile | 23.0% | 27.4% | 9.2% | 18.8% | 4.8% | 8.5% | 25.5% | 10.6% | 22.3% | 17.6% |
Key Takeaways
- Revenue for Q1 FY27 reached ₹64,157.71 lakhs, representing a significant 119.2% increase compared to the same quarter last year, though down from the record Q4 FY26.
- Net profit saw an exceptional year-on-year surge of 962.4% to ₹14,767.31 lakhs, driven by scale and favorable business mix compared to the low-base Q1 FY26.
- The company announced a long-term strategic CDMO partnership with Gland Pharma to establish dedicated manufacturing capacity for sterile APIs and microparticle depot products.
- Board approved a capacity expansion at Unit 1 (Bonthapally) adding 18 KL to the existing 376.5 KL to meet growing customer demand, with an investment of ₹39.8 crores.
- Geographic performance showed strong momentum in Europe and USA, which contributed ₹30,345.81 lakhs and ₹19,967.36 lakhs respectively to the quarterly revenue.
- Management noted that quarterly performance remains subject to inherent business lumpiness, emphasizing the importance of long-term trend lines over single-period fluctuations.
Management Guidance
Management maintains a long-term growth outlook of 18% to 20% CAGR, though warns of lumpiness across quarters. The focus remains on building an execution engine for large-scale programs and investing in high-margin complex peptides and R&D infrastructure.
Sentiment Shift
Stable
While the quarterly results showed a sequential dip from the exceptional Q4 FY26, the year-on-year growth remains massive and the new Gland Pharma collaboration provides a strategic growth catalyst.
Outlook
The company is transitioning to longer capital deployment cycles with a focus on peptide APIs and complex molecules. Near-term growth is visible through the existing commercial pipeline, supported by ongoing capacity expansions and a new R&D process development center.
From the Annual Report (Key Quotes)
“Demand for sterile APIs continues to grow as pharmaceutical companies advance increasingly complex injectable therapies.”
“The collaboration represents a significant expansion of the relationship... creating a dedicated manufacturing platform that aligns complementary capabilities.”
“Quarterly performance can be uneven, and it is best to evaluate the business over longer periods.”
Official Quarterly Documents
Ask AI about this quarter
This summary is AI-generated from Neuland Laboratories Limited's latest quarterly filing and earnings call. For informational purposes only — not investment advice.